CU23731A3 - RAGE FUSION PROTEINS AND METHODS OF USE - Google Patents

RAGE FUSION PROTEINS AND METHODS OF USE

Info

Publication number
CU23731A3
CU23731A3 CU20070034A CU20070034A CU23731A3 CU 23731 A3 CU23731 A3 CU 23731A3 CU 20070034 A CU20070034 A CU 20070034A CU 20070034 A CU20070034 A CU 20070034A CU 23731 A3 CU23731 A3 CU 23731A3
Authority
CU
Cuba
Prior art keywords
rage
fusion proteins
methods
rage fusion
polypeptide
Prior art date
Application number
CU20070034A
Other languages
Spanish (es)
Inventor
Shi Du Yan
David M Stern
Ann Marie Schmidt
Jeffrey C Webster
Ye E Tian
Robert Rothlein
Adnan M M Mjalli
Original Assignee
Trans Tech Pharma Inc
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trans Tech Pharma Inc, Univ Columbia filed Critical Trans Tech Pharma Inc
Priority to CU20070034A priority Critical patent/CU23731A3/en
Publication of CU23731A3 publication Critical patent/CU23731A3/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen proteínas que comprenden secuencias de polipéptidos RAGE unidas a un segundo polipéptido que no es RAGE. La proteína de fusión RAGE puede utilizar un dominio de polipéptido RAGE que comprende un sitio de unión a ligando de RAGE y un engarce interdominio unido directamente a un dominio CH2 de inmunoglobulina. También se describe el uso de las proteínas de fusión RAGE como agentes terapéuticos para las patologías mediadas por RAGE.Proteins comprising RAGE polypeptide sequences bound to a second polypeptide that is not RAGE are described. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to a CH2 immunoglobulin domain. The use of RAGE fusion proteins as therapeutic agents for RAGE-mediated pathologies is also described.

CU20070034A 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE CU23731A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU20070034A CU23731A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070034A CU23731A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CU23731A3 true CU23731A3 (en) 2011-11-15

Family

ID=45000142

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070034A CU23731A3 (en) 2007-02-02 2007-02-02 RAGE FUSION PROTEINS AND METHODS OF USE

Country Status (1)

Country Link
CU (1) CU23731A3 (en)

Similar Documents

Publication Publication Date Title
DOP2007000089A (en) RAG FUSION PROTEINS, FORMULATIONS AND EMPLOYMENT METHODS OF THE SAME
AR059377A1 (en) RAGE FUSION PROTEINS AND METHODS OF USE
CR8897A (en) FUSION RAGE PROTEINS AND EMPLOYMENT METHODS
ECSP077221A (en) RPGS FUSION PROTEINS AND METHODS OF USE
PE20151673A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
CY2022036I1 (en) ANTIGEN-BINDING PROTEINS ABLE TO BIND TO THYMIC STRATUM LYMPHOPOIETIN
DOP2014000083A (en) IMMUNO LINKERS AGAINST TNF
UY33366A (en) TYPE III FIBRONECTINE TO THE TENTH (10Fn3) OF SERIOALBUMIN UNION AND FUSION MOLECULES THAT UNDERSTAND THEM
ECSP11011445A (en) COMPOSITIONS AND METHODS FOR ANTIBODIES THAT ARE DIRECTED TO COMPLEMENT PROTEIN C3B
BR112018071307A2 (en) human cd40 binding agonist antibodies and uses thereof
GT200600240A (en) ANTI-TRKB MONOCLONAL ANTIBODIES AND USES OF THE SAME
CL2011001214A1 (en) Dimer of antibody-like protein comprising a tenth fibronectin type III domain (10fn3) that binds to igf-ir; covalently or non-covalently bound with a 10fn3 that binds to egfr; pharmaceutical composition that includes it; use of said composition to treat hyperproliferative disorders.
EA201170030A1 (en) IL-6-MEDIATED IMMUNOTHERAPY
HRP20190312T1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, which specifically bind to CD154 and their use
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
MX2016000611A (en) Fusokines involving cytokines with strongly reduced receptor binding affinities.
CR20120105A (en) THERAPEUTIC PROTEINS OF UNION TO DLL4
NI200900081U (en) TRKB AGONIST ANTIBODIES AND THEIR USES.
MX2017001712A (en) IMMUNOGLOBULIN FUSION PROTEINS OF THE SIGNAL ALFA REGULATORY PROTEIN (SIRP-ALFA).
EA200701211A1 (en) POLYPEPTIDES THAT ARE BINDING WITH BR3, AND THEIR APPLICATION
MX2012004868A (en) Human il-23 antigen binding proteins.
BRPI0919473A2 (en) FRIZZLED BINDING AGENTS AND THEIR USES
EP2352523A4 (en) ANTI-CD19 ENHANCED ANTIBODIES
ECSP12012272A (en) PROTEINS THAT JOIN TNF-?
PL2013236T3 (en) Antibodies that bind to the extracellular domain of the ALK tyrosine kinase receptor

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)